

Agenda **Novel Treatment Approaches for Non-Small-Cell Lung Cancer: A 2016 Update – Houston, TX – August, 27 2016**

8:25 AM Registration and Introduction *John V. Heymach, MD, PhD*

TARGETED THERAPY

8:30 AM Molecular Profiling in the Treatment of NSCLC: *John V. Heymach, MD, PhD*
Guidelines from the CAP, IASLC and AMP

9:00 AM Emerging Liquid Biopsy Mutation Testing for NSCLC *Lauren A. Byers, MD*

9:30 AM EGFR Inhibitors: Perspective on Molecular Markers and Patient Selection *Don L. Gibbons, MD, PhD*

10:00 AM BREAK

10:15 AM ALK Inhibitors: Perspective on Molecular Markers and Patient Selection *TBD*

10:45 AM **Panel Discussion and Case Presentation** *John V. Heymach, MD, PhD/ Lauren A. Byers, MD
Don L. Gibbons, MD, PhD/ TBD*

11:00 AM Emerging Strategies and Challenges Due to Secondary or Acquired EGFR *David Gerber, MD*
and ALK TKI Resistance

11:30 AM Identifying Therapeutic Options for NSCLC Patients without *TBD*
Actionable Mutations

12:00 PM Should All Patients with Advanced NSCLC Receive Maintenance *David Gerber, MD*
Therapy with Pemetrexed or Erlotinib?

12:30 PM Panel Discussion and Case Presentation *David Gerber, MD/TBD*

12:45 PM LUNCH

IMMUNOTHERAPY

1:45 PM Immunotherapy with Anti-PD-1 (Nivolumab, Pembrolizumab) and *Don L. Gibbons, MD, PhD*
Anti CTLA-4 (Ipilimumab) Antibodies in NSCLC

2:15 PM Immunotherapy with Anti-PD-L1 Antibodies (Atezolizumab and *John V. Heymach, MD, PhD*
Durvalumab) in NSCLC

2:45 PM BREAK

3:00 PM Immunotherapy and Targeted Therapy Options for Small Cell Lung Cancer *Lauren A. Byers, MD*

3:30 PM **Panel Discussion and Case Presentation** *Don Gibbons, MD, PhD
John V. Heymach, MD, PhD/Lauren A. Byers, MD*

SUPPORTIVE CARE ISSUES

3:45 PM Supportive Care Issues in the Era of Targeted Therapy and Immunotherapy of NSCLC *David Hui, MD*

4:15 PM **Adjournment** *John Heymach, MD, PhD*